From: HPV types, HIV and invasive cervical carcinoma risk in Kampala, Uganda: a case-control study
 | Squamous cell carcinoma N = 246 cases, 308 controlsa | Adenocarcinoma N = 39 cases, 308 controlsb | ||
---|---|---|---|---|
Adjustment factor | OR for HIV-positive vs. HIV-negative | 95% CI | OR for HIV-positive vs. HIV-negative | 95% CI |
Age | 1.5 | 0.9-2.3 | 1.1 | 0.4-2.7 |
Age + CD4 | 1.6 | 1.0-2.6 | 0.8 | 0.1-2.6 |
Age + CD4 + HPV16 | 1.6 | 0.9-2.9 | 0.5 | 0.1-1.8 |
Age + CD4 + HPV16-relatedc | 1.4 | 0.7-2.4 | 0.5 | 0.1-1.6 |
Age + CD4 + HPV18 | 1.4 | 0.8-2.4 | 0.3 | <1.2j |
Age + CD4 + HPV18-relatedd | 1.4 | 0.8-2.4 | 0.4 | 0.1-1.5 |
Age + CD4 + High-risk HPVe | 0.6 | 0.3-1.1 | 0.3 | <0.9j |
Age + CD4 + Low-risk HPVf | 1.9 | 1.1-3.2 | 0.8 | 0.2-2.6 |
Age + CD4 + Single HPV inf.g | 1.2 | 0.6-2.4 | 0.5 | 0.1-1.7 |
Age + CD4 + Multiple HPV inf.h | 1.8 | 1.1-3.0 | 0.6 | 0.1-2.0 |
Age + CD4 + Any HPV inf.i | 0.8 | 0.4-1.4 | 0.4 | 0.1-1.2 |